|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line显示文摘Worldwide prevalence of Helicobacter pylori(H.pylori) infection is approximately 50%,with the highest being in developing countries.We compared cure rates and tolerability(SE) of second-line anti-H.pylori levofloxacin/amoxicillin(LA)-based triple regimens vs standard quadruple therapy(QT).An English language literature search was performed up to October 2010.A meta-analysis was performed including randomized clinical trials comparing 7-or 10-d LA with 7-d QT.In total,10 articles and four abstracts were identified.Overall eradication rate in LA was 76.5%(95% CI:64.4%-97.6%).When only 7-d regimens were included,cure rate was 70.6%(95% CI:40.2%-99.1%),whereas for 10-d combinations,cure rate was significantly higher(88.7%;95% CI:56.1%-109.9%;P < 0.05).Main eradication rate for QT was 67.4%(95% CI:49.7%-67.9%).The 7-d LA and QT showed comparable efficacy [odds ratio(OR):1.09;95% CI:0.63-1.87],whereas the 10-d LA regimen was significantly more effective than QT(OR:5.05;95% CI:2.74-9.31;P < 0.001;I 2 = 75%).No differences were reported in QT eradication rates among Asian and European studies,whereas LA regimens were more effective in European populations(78.3% vs 67.7%;P = 0.05).Incidence of SE was lower in LA therapy than QT(OR:0.39;95% CI:0.18-0.85;P = 0.02).A higher rate of side effects was reported in Asian patients who received QT.Our findings support the use of 10-d LA as a simple second-line treatment for H.pylori eradication with an excellent eradication rate and tolerability.The optimal second-line alternative scheme might differ among countries depending on quinolone resistance. | Simona Di Caro Lucia Fini Yayha Daoud Fabio Grizzi Antonio Gasbarrini Antonino De Lorenzo Laura Di Renzo Sara McCartney Stuart Bloom | 2012 | World Journal of Gastroenterology2012，18，40： | 9 |
| 2 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 3 | Structure and receptor binding 显示文摘 | Jackson T King AM Stuart DI | 2003 | Virus Res2003，91，1： | 1 |
| 4 | Models which explain the inhibition of reverse transcriptase by HIV-1-specific ( thio ) carboxanilide derivatives 显示文摘 | Esnouf RM Stuart DI De Clercq E | 1997 | Biochem Biophys Commun1997，234，2： | 1 |
| 5 | Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer 显示文摘 | Robinson RC Radziejewski C Stuart DI Jones EY | 1995 | Biochemistry1995，34，13： | 1 |
| 6 | Stracture of tumor necrosis factor显示文摘 | Jones EY Stuart DI Walker NPC | 1989 | Nature1989，338，： | 1 |
| 7 | Stracture of tumor necrosis factor显示文摘 | Jones EY Stuart DI Waiker NPC | 1989 | Nature1989，338，： | 1 |
| 8 | Crystal structures of penicillin-binding protein 3 from Pseudomonas aeruginosa: comparison of native and antibiotic-bound forms 显示文摘 | Sainsbury S Bird L Rao V Shepherd SM Stuart DI Hunter WN Owens ILl Ren J | 2011 | J Mol Biol2011，405，1： | 1 |
| 9 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 1 |
| 10 | ESPript:Analysis of multiple sequence alignments in PostScript显示文摘 | Gouet P Courcelle E Stuart DI Metoz F | | 0，，： | 1 |
| 11 | Structure and receptor binding显示文摘 | Jackson T Stuart DI Fry E | 2003 | Virus Research2003，，： | 1 |
| 12 | Structure andreceptor binding 显示文摘 | JACKSON T KING AM STUART DI | 2003 | Virus Res2003，91，： | 1 |
| 13 | A mechanical explanation of RNA pseudoknot function in programmed ribosomal frameshifting 显示文摘 | NamyO Moran SJ Stuart DI | 2006 | Nature2006，441，7090： | 1 |
| 14 | The human low affinity Fcgamma receptors IIa, IIb, and Ili bind IgG with fast kinetics and distinct thermodynamic properties显示文摘 | Maenaka K van der Merwe PA Stuart DI | 2001 | J Biol Chem2001，276，44： | 1 |
| 15 | Structure and receptor binding 显示文摘 | Jackson T King AM Stuart DI | 2003 | Virus Res2003，91，1： | 1 |
| 16 | Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis显示文摘 | Kris V. Kowdley Stuart C. Gordon K. Rajender Reddy Lorenzo Rossaro David E. Bernstein Eric Lawitz Mitchell L. Shiffman Eugene Schiff Reem Ghalib Michael Ryan Vinod Rustgi Mario Chojkier Robert Herring Adrian M. Di Bisceglie Paul J. Pockros G. Mani Subrama | 2014 | The New England Journal of Medicine2014，，： | 1 |
| 17 | Structure of the Brain-Derived neurotrophic factor/Neurotrophin 3 het- erodimer 显示文摘 | Robinson RC Radziejewski C Stuart DI | 1995 | Biochemistry1995，34，13： | 1 |
| 18 | Structure and receptor binding显示文摘 | Jackson T King AM Stuart DI | 2003 | Virus Res2003，91，1： | 1 |
| 19 | Crystal structure of the human P58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class Ⅰ 显示文摘 | Maenake K Juji T Stuart DI | 1999 | Structure Fold Des1999，7，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员